Lars Rønn Olsen

Search results

• 2022

  Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib

  Purroy, N., Tong, Y. E., Lemvigh, C. K., Cieri, N., Li, S., Parry, E. M., Zhang, W., Rassenti, L. Z., Kipps, T. J., Slager, S. L., Kay, N. E., Lesnick, C., Shanafelt, T. D., Ghia, P., Scarfò, L., Livak, K. J., Kharchenko, P. V., Neuberg, D. S., Olsen, L. R., Fan, J., & 2 othersGohil, S. H. & Wu, C. J., 2022, In: Blood. 139, 14, p. 2252-2256

  Research output: Contribution to journal › Letter › peer-review
• 2019

  Getting the Most from Your High-Dimensional Cytometry Data

  Olsen, L. R., Pedersen, C. B., Leipold, M. D. & Maecker, H. T., 2019, In: Immunity. 50, 3, p. 535-536

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File
  23 Downloads (Pure)
• 2018

  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

  Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., Shukla, S. A., Hu, Z., Li, L., Le, P. M., Allesøe, R. L., Richman, A. R., Kowalczyk, M. S., Abdelrahman, S., Geduldig, J. E., Charbonneau, S., & 31 othersPelton, K., Iorgulescu, J. B., Elagina, L., Zhang, W., Olive, O., McCluskey, C., Olsen, L. R., Stevens, J., Lane, W. J., Salazar, A. M., Daley, H., Wen, P. Y., Chiocca, E. A., Harden, M., Lennon, N. J., Gabriel, S., Getz, G., Lander, E. S., Regev, A., Ritz, J., Neuberg, D., Rodig, S. J., Ligon, K. L., Suvà, M. L., Wucherpfennig, K. W., Hacohen, N., Fritsch, E. F., Livak, K. J., Ott, P. A., Wu, C. J. & Reardon, D. A., 2018, In: Nature. 565, p. 234-239 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  File

  • Neoantigen 100%
  • Glioblastoma 85%
  • T Cell 85%
  • Neoplasm 71%
  • Vaccine 42%
  148 Downloads (Pure)